# Bortezomib and Pemetrexed Disodium in Treating Patients With Advanced Non-Small Cell Lung Cancer or Other Solid Tumors

> **NCT00389805** · PHASE1,PHASE2 · COMPLETED · sponsor: **University of California, Davis** · enrollment: 27 (actual)

## Conditions studied

- Lung Cancer
- Unspecified Adult Solid Tumor, Protocol Specific

## Interventions

- **DRUG:** bortezomib
- **DRUG:** pemetrexed disodium
- **GENETIC:** gene expression analysis
- **GENETIC:** mutation analysis
- **GENETIC:** protein expression analysis
- **GENETIC:** reverse transcriptase-polymerase chain reaction
- **OTHER:** flow cytometry
- **OTHER:** immunoenzyme technique
- **OTHER:** immunohistochemistry staining method

## Key facts

- **NCT ID:** NCT00389805
- **Lead sponsor:** University of California, Davis
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-03
- **Primary completion:** 2006-12
- **Final completion:** 2007-06
- **Target enrollment:** 27 (ACTUAL)
- **Last updated:** 2018-10-31

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00389805

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00389805, "Bortezomib and Pemetrexed Disodium in Treating Patients With Advanced Non-Small Cell Lung Cancer or Other Solid Tumors". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT00389805. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*